Figure 1.
Figure 1. Change in serum complement C5 activity in response to ascending doses of coversin (Cov) and eculizumab (Ecu). R2 = patient sample, NC3 = normal control

Change in serum complement C5 activity in response to ascending doses of coversin (Cov) and eculizumab (Ecu). R2 = patient sample, NC3 = normal control

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal